108
Participants
Start Date
May 24, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
GLB-001
Administered orally according to the assigned treatment schedule
RECRUITING
China-Japan Friendship Hospital, Beijing
RECRUITING
Sheng Jing Hospital of China Medical Universtiy, Shenyang
RECRUITING
Huashan Hospital Affiliated to Fudan University, Shanghai
RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
RECRUITING
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei
RECRUITING
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
RECRUITING
The Second Hospital of Tianjin Medical Universtiy, Tianjin
RECRUITING
The First Affilicated Hospital, Zhejiang University School of Medicine, Hangzhou
RECRUITING
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
The First Hospital of Hebei Medical Universtiy, Shijiazhuang
Hangzhou GluBio Pharmaceutical Co., Ltd.
INDUSTRY